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Introduction
Tuberculosis is a disease caused by the 
mycobacteria Mycobacterium tuberculosis.(1) 
Currently it can be cured thanks to the 
antibiotics. 
The problem is that the ability of this bacteria 
can mutate and acquire drug resistance and 
become MDR-TB or XDR-TB. Figure 1 
presents the cases of TB and MDR-TB in 
Europe from 2005 until 2012
Objectives:
- Define the mechanisms of intrinsic and 
acquired drug resistance in M. 
tuberculosis
- Describe the drug resistance mutations 
and their molecular changes.
Fig 1:TB and MDR-TB cases in Europe (WHO). Source: 
https://extranet.who.int/sree/Reports?op=vs&path=/WHO_HQ_Reports/G2/PR
OD/EXT/MDRTB_Indicators_charts 
Intrinsic antibiotic resistance mechanism
- Mycobacterial cell wall: The Figure 2 shows the structure of 
the cell wall. The peptidoglycan and the arabinogalactan
layer, are covalently linked to a layer of mycolic acids that 
prevent the  drug diffusion between the inside and the outside 
of the bacteria.(4)
- Porins: Research demonstrate that MspA porin in M. 
smegmati makes the bacteria be more sensitive towards the 
antibiotics. Figure 3 shows the molecular structure of the 
MspA porin. There is the possibility that the 
absence/presence of M. tuberculosis MctB and OmpA porins
may be linked at drug resistance.(5)
- Efflux pumps: The main function is to expel waste and toxic 
substances through the cell wall. There are 18 pumps 
codified in its genome giving it a low-level drug resistance. 
The main problem would be a mutation that causes an 
overexpression of this efflux pumps.(6)
Conclusions:
As we could see in this review, besides the classic mutations there are other kinds of unknown of molecular changes. That’s why we have to keep improving the molecular 
tools in order to know better its drug resistance mechanism. After that we will be able to make more rational antibiotics or to reform the current treatments. It is also 
important to use the molecular tools to study how MDR-TB and XDR-TB strains work and to avoid their global expansion. However it’s important to keep investigating to 
discover new possible targets and to develop antibiotics which are effective despite their mutations.
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Drug Mode of action Gene Gene function Role Mutation
First-
line
Isoniazid Inhibition of mycolic acid biosynthesis 
and other metabolic processes
katG
inhA
ndh
ahpC
Catalase-peroxidase
Enoyl ACP reductasa
NADH dehydrogenase II
Alkyl hidroperoxidase
Prodrug activation
Drug target
Activity modulation
Resistance marker
Ser-315-Thr
-15C->T promotor site
Arg-13-Cys and Val-18-Ala 
--
Rifampicin Inhibition of transcription rpoB B-subunit of RNA polymerase Drug target Ser-450-Leu
Pyrazinamide Inhibition of trans-translation pncA
rpsA
Pyrazinamidase
S1 ribosomal protein
Prodrug activation
Drug target
Asp-12-Ala/Asn, Leu-85-Pro
Deletion Ala438
Ethambutol Inhibition of arabinogalactan
synthesis
embCAB
embR
Arabinosyl transferases
embCAB transcription regulator
Drug target
Drug target expression
embB: Met-306-Val/Ile/Leu
Unknown
Streptomycin Inhibition of translation rpsL
rrs
gidB
S12 ribosomal protein
16S rRNA
16S rRNA methyltransferase
Drug target
Drug target
Target modification
Lis-43-Arg
A-1401-G
Second
-line
Amikacin/Kanamycin/ 
Capreomycin/ Vancomycin
Inhibition of translation rrs
tlyA
Eis
16S rRNA
16S/23S rRNA methyltransferase
enhanced intracellular survival
Drug target
Drug target
Drug resistance
A-1401-G
G-223-T
--
Ethionamide Inhibition of mycolic acid biosynthesis ethA
inhA
Ndh
Flavin monooxygenase
Enoyl ACP reductase
NADH dehydrogenase II
Prodrug activation
Drug target
Activity modulation
--
Ile-21-Thr/Val and
Arg-13-Cys and Val-18-Ala 
Fluoroquinolones Inhibition of DNA gyrase gyrA
gyrB
DNA gyrase subunit A
DNA gyrase subunit B
Drug target
Drug binding (target)
Ala-90-Val and Asp-94-Gly/Tyr
Asn-533-Thr
P-aminosalicylic acid (PAS) Unknown thyA thymidylate synthase A Drug resistance Confers susceptibility: Val-261-Gly
Linezolid Inhibition protein biosynthesis Rrl 50S ribosomal subunit Drug target G-2061-T and G-2576-T
Macrolides Increase cell wall permeability erm 37 23S rRNA methyltransferasa Drug resistance Intrinsic resistance
Cicloserine Inhibition peptidoglycan biosynthesis -- -- -- --
New-
Drugs
SQ109 Inhibition cell wall biosynthesis mmpL3 Mmpl3 transporter Drug target Ala-700-Thr and Glut-40-Arg
TMC207 Inhibition ATP synthase atpE ATP synthase subunit C Drug target Ala-63-Pro and Iso-66-Met 
NAS-21/ NAS-91 analogues Inhibition fatty acid biosynthesis hadB FAS-II dehydratase Drug target Unknown
Benzothiazinones Inhibition arabinan biosynthesis dprE1 decaprenylphosphoryl-beta-D-ribose oxidase Drug target Cys-387-Ser
PA-824
OPC- 67683
NO donor/ Inhibition cell wall 
biosynthesis
Inhibition mycolic acid biosynthesis
Ddn deazaflavin-dependent nitroreductase Prodrug activation Unknown
Fig 2: Mycobacterial cell wall of M. tuberculosis. Altered 
source: img.docstoccdn.com/thumb/orig/27038162
Fig 3: Molecular structure of 
MspA porin. Source: 
http://upload.wikimedia.org/
wikipedia/commons/0/0f/1uu
n_opm.gif 
Chart 1. Antibiotics against M. tuberculosis, their targets and their main mutation. Source based on: (3)
Spontaneous mutations are the only mechanism that can make M. tuberculosis a drug resistance bacteria. In 
chart 1 we can observe the discovered mutations that M. tuberculosis can have to protect itself against antibiotics.
